Heart Failure Management

Pharmacological Treatment

• The American College of Cardiology recommends lisinopril as a first-line agent for hypertension, with a target dose of 20-40 mg once daily, particularly beneficial in patients with diabetes, proteinuria, and left ventricular hypertrophy 1
• The American College of Cardiology recommends metoprolol as an effective agent for hypertension control, with a target dose of 200 mg once daily (metoprolol succinate), particularly beneficial in patients with coronary artery disease, tachyarrhythmias, and post-myocardial infarction 1
• Lisinopril is recommended for all patients with heart failure with reduced ejection fraction (HFrEF) (LVEF ≤40%) 1
• Beta-blockers like metoprolol should be initiated at low doses and gradually titrated up in heart failure patients, with contraindications including asthma, severe bronchial disease, symptomatic bradycardia or hypotension, advanced heart block without a pacemaker, and cardiogenic shock 2, 3, 4, 5
• Renal function and potassium levels should be monitored when using lisinopril, especially in combination with other medications affecting the RAAS system, with regular monitoring of serum potassium essential during initiation and dose titration 1, 2

Treatment Approach

• The treatment approach for heart failure with reduced EF (≤40%) involves starting with an ACE inhibitor (lisinopril) at a low dose, followed by the addition of a beta-blocker (metoprolol succinate) when the patient is stable, then a mineralocorticoid receptor antagonist, and finally an SGLT2 inhibitor, with target doses of lisinopril 20-40 mg daily and metoprolol succinate 200 mg daily, as recommended by the American College of Cardiology and American Heart Association 1, 6, 7
• The American Heart Association (AHA) and American College of Cardiology (ACC) define HFrEF as LVEF ≤40%, which determines the evidence-based treatment approach, including the use of ACE inhibitors or ARBs, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors to reduce mortality, hospitalizations, and improve quality of life 6, 8, 9, 7
• Diuretics should be used for symptom relief in patients with evidence of fluid overload, with loop diuretics preferred over thiazides for most HFrEF patients, and patients should be advised to report deterioration but not to stop therapy without consulting their physician 10, 11
• The recommended dosing protocol for beta-blockers is as follows:

12, 6, 13

• Close monitoring of heart rate and symptoms is essential when metoprolol must be used in a patient with borderline bradycardia (HR 50-60 bpm) for compelling indications, and serial echocardiography should be used to follow LVEF over time and assess for improvement, with continued HFrEF treatment recommended even if LVEF improves to >40% 11, 6

Special Considerations

• For patients with atrial fibrillation, anticoagulation is recommended if there are no contraindications, and ventricular rate should be controlled with beta-blockers or digoxin, as recommended by the American Heart Association and American College of Cardiology 9, 14
• For patients with underlying coronary artery disease, antiplatelet therapy should be considered, and evaluation for revascularization and optimization of lipid management are recommended, as recommended by the American College of Cardiology 8
• Cardioselective agents (bisoprolol, metoprolol, nebivolol) are preferred in patients with bronchospastic airway disease requiring beta blockade, as recommended by the American Heart Association and European Society of Cardiology 15, 16

Evidence and Outcomes

• The CIBIS-II trial demonstrated that bisoprolol reduced all-cause mortality by 34% compared to placebo in heart failure patients, and carvedilol reduced mortality risk by 38% and risk of death/hospitalization by 31% in heart failure patients, as recommended by the American College of Cardiology 17, 18
• Metoprolol succinate has been shown to reduce all-cause mortality by 34-35% in patients with systolic heart failure, as recommended by the American College of Cardiology 1, 19, 17, 20
• Beta-blockers like metoprolol can be used effectively in combination with ACE inhibitors/ARBs, diuretics, and SGLT2 inhibitors in heart failure management, as recommended by the American Heart Association and European Society of Cardiology 17, 21, 22